JNJ JOHNSON & JOHNSON

NYSE jnj.com


$ 199.22 $ 3.65 (1.86 %)    

Monday, 17-Nov-2025 15:45:48 EST
QQQ $ 601.79 $ -5.20 (-0.85 %)
DIA $ 465.86 $ -5.48 (-1.16 %)
SPY $ 664.33 $ -6.26 (-0.93 %)
TLT $ 89.12 $ 0.22 (0.25 %)
GLD $ 370.69 $ -4.31 (-1.15 %)
$ 199.58
$ 196.53
$ 199.16 x 129
$ 199.23 x 16
$ 195.97 - $ 200.25
$ 137.37 - $ 200.28
12,852,836
na
480.85B
$ 0.30
$ 19.14
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-22-2025 09-28-2025 10-Q
2 07-24-2025 06-29-2025 10-Q
3 04-23-2025 03-30-2025 10-Q
4 02-13-2025 12-29-2024 10-K
5 10-23-2024 09-29-2024 10-Q
6 07-25-2024 06-30-2024 10-Q
7 05-01-2024 03-31-2024 10-Q
8 02-16-2024 12-31-2023 10-K
9 10-27-2023 10-01-2023 10-Q
10 10-27-2023 10-01-2023 10-Q
11 07-31-2023 07-02-2023 10-Q
12 04-28-2023 04-02-2023 10-Q
13 02-16-2023 01-01-2023 10-K
14 10-27-2022 10-02-2022 10-Q
15 07-29-2022 07-03-2022 10-Q
16 04-29-2022 04-03-2022 10-Q
17 02-17-2022 01-02-2022 10-K
18 10-29-2021 10-03-2021 10-Q
19 07-29-2021 07-04-2021 10-Q
20 04-30-2021 04-04-2021 10-Q
21 02-22-2021 01-03-2021 10-K
22 10-23-2020 09-27-2020 10-Q
23 07-24-2020 06-28-2020 10-Q
24 04-29-2020 03-29-2020 10-Q
25 02-18-2020 12-29-2019 10-K
26 10-28-2019 09-29-2019 10-Q
27 07-29-2019 06-30-2019 10-Q
28 05-01-2019 03-31-2019 10-Q
29 02-20-2019 12-30-2018 10-K
30 10-31-2018 09-30-2018 10-Q
31 08-02-2018 07-01-2018 10-Q
32 05-01-2018 04-01-2018 10-Q
33 02-21-2018 12-31-2017 10-K
34 11-02-2017 10-01-2017 10-Q
35 08-03-2017 07-02-2017 10-Q
36 05-08-2017 04-02-2017 10-Q
37 02-27-2017 01-01-2017 10-K
38 11-04-2016 10-02-2016 10-Q
39 08-04-2016 07-03-2016 10-Q
40 05-10-2016 04-03-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hedge-funds-snap-up-eli-lilly-united-healthcare-and-more-putting-healthcare-etfs-back-in-the-spotlight

With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensi...

 johnson--johnson-adds-prostate-cancer-candidate-in-around-3-billion-halda-deal

Johnson & Johnson buys Halda for $3.05 billion, adding a prostate cancer candidate as new Tremfya Phase 3b data show sustai...

 court-rejects-bid-to-block-kenvues-398-million-shareholder-payout-in-tylenol-safety-dispute

Texas judge rejects bid to block Kenvue's $398 million dividend and declines to restrict Tylenol marketing as the company f...

 johnson--johnson-reports-tremfya-delivers-sustained-joint-protection-and-significant-symptom-improvement-through-48-weeks-in-phase-3b-psoriatic-arthritis-study

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained thr...

 bristol-myers-faces-another-trial-disappointment-as-heart-drug-milvexian-fails-to-show-efficacy

Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and ...

 these-20-stocks-now-make-up-half-of-the-sp-500heres-why-thats-risky

A new report shows the S&P 500 is now more concentrated than ever, with 20 companies making up over 50% of its value, drive...

 fda-clears-johnson--johnsons-darzalex-faspro-enabling-early-intervention-in-myeloma-progression

The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on...

 fda-fast-tracks-6-more-drugs---obesity-and-cancer-drugs-included

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescr...

Core News & Articles

Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Adm...

Core News & Articles

https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-fights-stop-manufacturer-tylenol-fraudulently-pa...

 fda-approves-daratumumab-and-hyaluronidase-fihj-for-high-risk-smoldering-multiple-myeloma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smolde...

 johnson--johnson-announces-fda-approval-of-caplyta-as-adjunctive-therapy-with-antidepressants-to-treat-major-depressive-disorder-in-adults

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateper...

 options-corner-kimberly-clarks-implosion-offers-an-unusual-informational-arbitrage-opportunity

Although Kimberly-Clark suffered a huge blow after announcing its Kenvue buyout, KMB stock is flashing a quantitative contraria...

 alvotech-shares-plunge-33-after-fda-flags-issues

Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 rev...

Core News & Articles

Buffett Sells Stocks

 kimberly-clark-stock-plunges-over-16-kenvue-surges-20-in-monday-pre-market-whats-going-on

Shares of Kimberly-Clark Corporation (NASDAQ: KMB) plunged 16.49% during the pre-market trading session on Monday, after it ann...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION